Can-Fite Biopharma (NYSE American: CANF; TASE: CANF) has announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer.
According to Can-Fite, the data from the fully enrolled study demonstrate preliminary evidence of clinical activity, including durable disease stabilization in a heavily pretreated patient population, along with the previously reported favorable safety profile. Among other findings, 35% of patients remain on therapy, including one patient who has continued treatment for more than 16 months.
In a statement, Pnina Fishman, chairperson and CSO of Can-Fite, commented, “As we continue to analyse the data, we are encouraged by the emerging signal of durable disease stabilization observed in this study. Importantly, a meaningful proportion of patients remain on therapy for extended periods, supporting the continued clinical development of namodenoson in pancreatic cancer.”
